MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine TherapyGeorge W. Sledge, Antonio Llombart‐Cussac, Norikazu Masuda et al.|Journal of Clinical Oncology|2017Cited by 1.7k
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyJavier Cortés, Chris Twelves, Joyce O’Shaughnessy et al.|The Lancet|2011Cited by 1.1k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2George W. Sledge, Antonio Llombart‐Cussac, Masakazu Toi et al.|JAMA Oncology|2019Cited by 983
P3.01-98 The Onset and Clinical Course of Transverse Myelopathy with Lung CancerTetsuo Tani, Han Koh, Takahiro Fukui et al.|Journal of Thoracic Oncology|2018Cited by 0